AI in healthcare market to reach USD 208.85 bn by 2030 

The artificial intelligence (AI) in healthcare market is anticipated to reach USD 208.85 billion by 2030 and is anticipated to expand at a CAGR of 42.32% during the forecast period, according to a new report by Driven Market Research. The increasing demand for artificial intelligence in healthcare sector for more efficient, accurate, and improved patient care is a primary reason for the growth of the market. For instance, in August 2023, a survey conducted by Morgan Stanley found that 94% of healthcare companies are using AI and machine learning. The money spent on these technologies is expected to increase from 5.7% of their budget in 2022 to 10.5% in 2024. This shows a significant rise in investment in AI and machine learning within the healthcare industry.

The healthcare industry is increasingly adopting artificial intelligence (AI) and robotics to enhance patient care and operational efficiency. AI is utilized for accurate diagnosis and treatment predictions, while robotics support complex surgeries and rationalize routine tasks. This integration aims to improve precision, reduce human error, and optimize overall healthcare delivery. For instance, AI-driven systems such as IBM Watson are helping doctors identify the most effective treatment plans for cancer patients by analyzing vast amounts of medical data. Meanwhile, robotics is playing a crucial role in complex surgeries, such as the da Vinci Surgical System, which allows surgeons to perform minimally invasive procedures with enhanced precision.

AI is being increasingly integrated into drug discovery and development to enhance efficiency and effectiveness. It assists in analyzing large datasets to identify promising drug leads and predict their potential effects. This approach accelerates the development process, reduces costs, and improves the probability of discovering effective treatments. For instance, a review published in Drug Discovery Today Journal in January 2024 highlighted the application of deep generative AI models in de novo drug design. These AI models use sophisticated algorithms to design new, unique molecules from scratch, optimizing them for the desired biological activity. This allows researchers to explore previously uncharted chemical spaces, accelerating the discovery of novel drug candidates. Driven Market Research